Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of ipatasertib versus placebo with abiraterone + prednisone/prednisolone in metastatic castration-resistant prostate cancer
CTR20171524Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ipatasertib in prostate cancer (PCa), sponsored by Roche. Started Jul 2018; status: completed.
02
Drugs
ipatasertib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20171524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171524.